Interaction Between the Distribution of Diabetic Retinopathy Lesions and the Association of Optical Coherence Tomography Angiography Scans With Diabetic Retinopathy Severity.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 12 2020
Historique:
pubmed: 30 10 2020
medline: 23 2 2021
entrez: 29 10 2020
Statut: ppublish

Résumé

Studies have not yet determined whether the distribution of lesions in the retinal periphery alters the association between the severity of diabetic retinopathy (DR) and macular vessel density. To evaluate the association of DR lesion distribution with optical coherence tomography angiography (OCTA) metrics and DR severity. This cross-sectional observational study was conducted at a tertiary care center for diabetic eye disease among 225 patients with type 1 or 2 diabetes who had undergone imaging between February 15, 2016, and December 31, 2019. Optical coherence tomography angiography 3 × 3-mm macular scans and ultra-widefield color imaging. Optical coherence tomography angiography vessel density in the superficial capillary plexus, intermediate capillary plexus, and deep capillary plexus and choriocapillaris flow density. The severity of DR and the predominantly peripheral lesions (PPL) were evaluated from ultra-widefield color imaging. The study evaluated 352 eyes (225 patients; 125 men [55.6%]; mean [SD] age, 52.1 [15.1] years), of which 183 eyes (52.0%) had mild nonproliferative diabetic retinopathy (NPDR), 71 eyes (20.2%) had moderate NPDR, and 98 eyes (27.8%) had severe NPDR or proliferative diabetic retinopathy (PDR). In eyes with no PPL (209 [59.4%]), the mean (SD) vessel density in the superficial capillary plexus (mild NPDR, 38.1% [4.7%]; moderate NPDR, 36.4% [4.6%]; severe NPDR or PDR, 34.1% [4.1%]; P < .001) and the deep capillary plexus (mild NPDR, 45.8% [3.0%]; moderate NPDR, 45.8% [2.2%]; severe NPDR or PDR, 44.5% [1.9%]; P = .002), as well as the mean (SD) choriocapillaris flow density (mild NPDR, 69.7% [6.2%]; moderate NPDR, 67.6% [5.6%]; severe NPDR or PDR, 67.1% [5.6%]; P = .01), decreased with increasing DR severity. These associations remained statistically significant even after correcting for age, signal strength index, spherical equivalent, duration of diabetes, type of diabetes, and correlation between eyes of the same patient. In eyes with PPL (143 [40.6%]), mean (SD) vessel density in the superficial capillary plexus (mild NPDR, 34.1% [4.1%]; moderate NPDR, 35.2% [4.1%]; severe NPDR or PDR, 36.0% [4.3%]; P = .42) and the deep capillary plexus (mild NPDR, 44.5% [1.7%]; moderate NPDR, 45.4% [1.4%]; severe NPDR or PDR, 44.9% [1.5%]; P = .81), as well as the mean (SD) choriocapillaris flow density (mild NPDR, 67.1% [5.6%]; moderate NPDR, 69.3% [4.6%]; severe NPDR or PDR, 68.3% [5.6%]; P = .49), did not appear to change with increasing DR severity. These results suggest that central retinal vessel density is associated with DR severity in eyes without, but not with, PPL. These findings suggest a potential need to stratify future optical coherence tomography angiography studies of eyes with DR by the presence or absence of PPL. If DR onset and worsening are associated with the location of retinal nonperfusion, assessment of global retinal nonperfusion using widefield angiography may improve the ability to evaluate DR severity and risk of DR worsening over time.

Identifiants

pubmed: 33119083
pii: 2772367
doi: 10.1001/jamaophthalmol.2020.4516
pmc: PMC7596681
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1291-1297

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK036836
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY024702
Pays : United States

Références

Ophthalmology. 1991 May;98(5 Suppl):786-806
pubmed: 2062513
Opt Express. 2012 Feb 13;20(4):4710-25
pubmed: 22418228
Semin Ophthalmol. 2019;34(4):189-197
pubmed: 31188056
Ophthalmology. 2013 Dec;120(12):2587-2595
pubmed: 23778092
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT362-70
pubmed: 27409494
Ophthalmology. 1991 May;98(5 Suppl):823-33
pubmed: 2062515
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ophthalmol Retina. 2019 Oct;3(10):835-842
pubmed: 31257069
Ophthalmology. 2015 Dec;122(12):2465-72
pubmed: 26350546
Am J Ophthalmol. 2012 Sep;154(3):549-559.e2
pubmed: 22626617
Retina. 2015 Nov;35(11):2163-80
pubmed: 26428607
Ophthalmology. 1984 Dec;91(12):1431-9
pubmed: 6084212
Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):53
pubmed: 32866267
Br J Ophthalmol. 2020 Dec;104(12):1762-1767
pubmed: 32111607
Transl Vis Sci Technol. 2020 Jun 05;9(7):10
pubmed: 32832217
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5548-5555
pubmed: 29075766
Retina. 2020 Oct;40(10):1964-1971
pubmed: 31800461
Ophthalmology. 2019 Dec;126(12):1685-1694
pubmed: 31383483
Ophthalmic Surg Lasers Imaging Retina. 2018 Dec 1;49(12):925-931
pubmed: 30566699
Retina. 2016 Nov;36(11):2039-2050
pubmed: 27205895
JAMA Ophthalmol. 2019 Nov 27;:
pubmed: 31774456
Retina. 2015 Nov;35(11):2353-63
pubmed: 26465617
Retina. 2019 Mar;39(3):426-434
pubmed: 30664126
Sci Rep. 2017 Feb 10;7:42201
pubmed: 28186181
JAMA Ophthalmol. 2018 Aug 1;136(8):929-936
pubmed: 29902297
Ophthalmology. 2019 Dec;126(12):1675-1684
pubmed: 31358386
JAMA Ophthalmol. 2019 Jan 1;137(1):65-73
pubmed: 30347105
Ophthalmology. 2015 May;122(5):949-56
pubmed: 25704318
Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):725-733
pubmed: 31989286
Ophthalmology. 2019 Nov;126(11):1527-1532
pubmed: 31383482
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4292-4298
pubmed: 30167660

Auteurs

Mohamed Ashraf (M)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Ophthalmology Department, Alexandria Faculty of Medicine, Alexandria, Egypt.

Konstantina Sampani (K)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Abdulrahman Rageh (A)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.

Paolo S Silva (PS)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Lloyd Paul Aiello (LP)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Jennifer K Sun (JK)

Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH